Model SV40-transformed fibroblast lines for metabolic studies of human prosaposin and acid ceramidase deficiencies

被引:27
作者
Chatelut, M
Harzer, K
Christomanou, H
Feunteun, J
Pieraggi, MT
Paton, BC
Kishimoto, Y
OBrien, JS
Basile, JP
Thiers, JC
Salvayre, R
Levade, T
机构
[1] CHU RANGUEIL,INST LOUIS BUGNARD,INSERM,U466,LAB BIOCHIM,F-31403 TOULOUSE,FRANCE
[2] UNIV TUBINGEN,INST HIRNFORSCH,NEUROCHEM LAB,TUBINGEN,GERMANY
[3] LAB NEUROCHEM & MOL BIOL,ATHENS,GREECE
[4] INST GUSTAVE ROUSSY,CNRS,URA 1967,LAB GENET ONCOL,VILLEJUIF,FRANCE
[5] WOMENS & CHILDRENS HOSP,DEPT CHEM PATHOL,ADELAIDE,SA,AUSTRALIA
[6] UNIV CALIF SAN DIEGO,CTR MOL GENET,DEPT NEUROSCI,LA JOLLA,CA 92093
关键词
prosaposin; saposin; ceramide; ceramidase; sphingomyelin; lysosomes; lysosomal storage disease; fibroblasts (SV40-transformed);
D O I
10.1016/S0009-8981(97)06527-3
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Skin fibroblasts from patients with Farber disease (acid ceramidase deficiency) and from two siblings of the only known family affected with prosaposin deficiency were transformed by transfection with a plasmid carrying the SV40 large T antigen. The prosaposin-deficient transformed cell lines conserved their original metabolic defects, and in particular they were free of detectable immunoreactivity when using anti-saposin B and anti-saposin C antisera. Ultrastructurally, the cells contained heterogeneous lysosomal storage products. As found for their parental cell lines, the SV40-transformed fibroblasts exhibited deficient in vitro activities of lysosomal ceramidase and beta-galactosylceramidase, but a normal activity of acid sphingomyelinase. As observed for SV40-transformed fibroblasts from Farber disease, degradation of radioactive glucosylceramide or low density lipoprotein-associated radiolabelled sphingomyelin by the prosaposin-deficient cells in situ showed a clear impairment in the turnover of lysosomal ceramide. Ceramide storage in prosaposin-deficient cells was also demonstrated by ceramide mass determination. In contrast to acid ceramidase deficient cells, both the accumulation of ceramide and the reduced in vitro activity of acid ceramidase in cells from prosaposin deficiency could be corrected by addition of purified saposin D. The data confirm that prosaposin is required for lysosomal ceramide degradation, but not for sphingomyelin turnover. The SV40-transformed fibroblasts will be useful for pathophysiological studies on human prosaposin deficiency. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:61 / 76
页数:16
相关论文
共 36 条
  • [1] STIMULATION OF ACID CERAMIDASE ACTIVITY BY SAPOSIN-D
    AZUMA, N
    OBRIEN, JS
    MOSER, HW
    KISHIMOTO, Y
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1994, 311 (02) : 354 - 357
  • [2] PROSAPOSIN DEFICIENCY - FURTHER CHARACTERIZATION OF THE SPHINGOLIPID ACTIVATOR PROTEIN-DEFICIENT SIBS - MULTIPLE GLYCOLIPID ELEVATIONS (INCLUDING LACTOSYLCERAMIDOSIS), PARTIAL ENZYME DEFICIENCIES AND ULTRASTRUCTURE OF THE SKIN IN THIS GENERALIZED SPHINGOLIPID STORAGE DISEASE
    BRADOVA, V
    SMID, F
    ULRICHBOTT, B
    ROGGENDORF, W
    PATON, BC
    HARZER, K
    [J]. HUMAN GENETICS, 1993, 92 (02) : 143 - 152
  • [3] A simple method for screening for Farber disease on cultured skin fibroblasts
    Chatelut, M
    Feunteun, J
    Harzer, K
    Fensom, AH
    Basile, JP
    Salvayre, R
    Levade, T
    [J]. CLINICA CHIMICA ACTA, 1996, 245 (01) : 61 - 71
  • [4] ISOLATION OF 2 FORMS OF AN ACTIVATOR PROTEIN FOR THE ENZYMIC SPHINGOMYELIN DEGRADATION FROM HUMAN GAUCHER SPLEEN
    CHRISTOMANOU, H
    KLEINSCHMIDT, T
    [J]. BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1985, 366 (03): : 245 - 256
  • [5] Ouchterlony double immunodiffusion method demonstrates absence of ferritin immunoreactivity in visceral organs from nine patients with Niemann-Pick disease type C
    Christomanou, H
    Harzer, K
    [J]. BIOCHEMICAL AND MOLECULAR MEDICINE, 1996, 58 (02) : 176 - 183
  • [6] IMMUNOCHEMICAL CHARACTERIZATION OF 2 ACTIVATOR PROTEINS STIMULATING ENZYMATIC SPHINGOMYELIN DEGRADATION INVITRO ABSENCE OF ONE OF THEM IN A HUMAN GAUCHER DISEASE VARIANT
    CHRISTOMANOU, H
    AIGNESBERGER, A
    LINKE, RP
    [J]. BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1986, 367 (09): : 879 - 890
  • [7] FOLCH J, 1957, J BIOL CHEM, V226, P497
  • [8] CORRECTION OF MUCOLIPIDOSIS-III IN-VITRO BY GENE-TRANSFER
    FOWLER, ML
    FAN, YS
    MUELLER, OT
    HENRY, WM
    SHOWS, TB
    [J]. GENOMICS, 1993, 18 (02) : 236 - 243
  • [9] Targeted disruption of the mouse sphingolipid activator protein gene: A complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids
    Fujita, N
    Suzuki, K
    Vanier, MT
    Popko, B
    Maeda, N
    Klein, A
    Henseler, M
    Sandhoff, K
    Nakayasu, H
    Suzuki, K
    [J]. HUMAN MOLECULAR GENETICS, 1996, 5 (06) : 711 - 725
  • [10] ACTIVATOR PROTEINS AND TOPOLOGY OF LYSOSOMAL SPHINGOLIPID CATABOLISM
    FURST, W
    SANDHOFF, K
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1126 (01) : 1 - 16